About Horizon Therapeutics
Horizon Therapeutics is a Healthcare company based in Dublin (Ireland) founded in 2008, and was acquired by Amgen in December 2022. Horizon Therapeutics has raised $61.78 million across 7 funding rounds from investors including Amgen. Horizon Therapeutics has completed 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma. Its chief executive, as recorded, is Timothy Walbert. Horizon Therapeutics offers products and services including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model. Its focus areas include Life Sciences, Orthopedics, Drugs and Diversified. Its legal entity is Amgen Inc.
Company details
Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogrens syndrome.
- Headquarters Dublin, Ireland
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website horizontherapeutics.com
- Social LinkedIn X Facebook
- Acquired by Amgen (Dec 2022)
- Legal Name Amgen Inc.
- Annual Revenue$617.41 M (USD)14as on Dec 31, 2022
- Total Equity Funding$61.78M (USD)
in 7 rounds
- Latest Funding Round$69.4M (USD), Post-IPO
Oct 2014
- Investors
- Investments & AcquisitionsCrealta Pharmaceuticals
& 4 more
- Acquired byAmgen
(Dec 2022)
Products & Services of Horizon Therapeutics
Horizon Therapeutics offers a comprehensive portfolio of products and services, including Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model.
Treatments for serious diseases using biologic agents
Platform for screening compounds in drug design
Machine learning for accelerating clinical trials
Funding Insights of Horizon Therapeutics
Horizon Therapeutics has successfully raised a total of $61.78M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $69.4 million completed in October 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61.78M
- Total Rounds 7
- Last Round Post-IPO — $69.4M
- First Round $17M
(Oct 2008)
All 7 funding rounds of Horizon Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2014 | $69.4M | Post-IPO | – | – | – |
| Nov 2013 | $150M | Post-IPO | – | – | – |
| Mar 2012 | $65.93M | Post-IPO | – | – | – |
| Apr 2010 | $36.78M | Series C | – | – | – |
| Apr 2010 | Debt – Conventional | – | – | – | |
| Feb 2010 | $8M | Series B | – | – | – |
| Oct 2008 | $17M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in Horizon Therapeutics
Horizon Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Amgen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States |
Investor details for Horizon Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Horizon Therapeutics
1109 people are tracked at Horizon Therapeutics (432 in leadership, 47 in board & advisors, 630 in team).
| Name | Role | Group |
|---|---|---|
Timothy Walbert | Chairman, President & CEO | Leadership |
Seamus Lyons | Sr. Director Manufacturing | Leadership |
Alma Holden | Associate Director Validation | Leadership |
Francisco J Aguado-Rodriguez | Director Of Quality - Data Integrity And Ops Management Review GPO | Leadership |
Vivian Tu | Senior Director, Competitive Intelligence | Leadership |
Amro Essmat | Director , Quality - Regional Quality Head TMEA - Turkey, Middle East & Africa At Amgen | Leadership |
Miriam O'Sullivan | Executive Director Plant Manager | Leadership |
Mara Wachholder | Director, Treasury | Leadership |
Thiago Pastore | Human Resources Director, Brazil | Leadership |
Chris Pacheco | Director Manufacturing | Leadership |
Aditya Tulsyan | Associate Director Data Sciences, Operations | Leadership |
Andreas Reichelt | Senior Director Contract Manufacturing | Leadership |
Laura Cooke | Program Management Executive Director | Enterprise Transformation | Leadership |
Ned Endler | Executive Director US Trade, Channel Strategy And Execution | Leadership |
Amy Belisle | Associate Director Quality | Leadership |
Susie Tappouni | Head of Corporate Affairs | Leadership |
Kim Worrell | Associate Director HR Systems & Solutions | Leadership |
Jessica Vargas | Director, HR Business Partner | Leadership |
Mark Corder | Senior Director | Leadership |
Tara U. | Director, Global Corporate Affairs, Operations | Leadership |
1089 more people are available in the full profile.
Complete people profiles for Horizon Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Horizon Therapeutics
Horizon Therapeutics has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include Crealta Pharmaceuticals, Nitec Pharma and Raptor Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of biologics for treating severe inflammation and autoimmune diseases | vielabio.com | Gaithersburg, United States | 2017 | Dec 2020 | $3.05B | |
Small molecule therapeutics for rare diseases are developed. | raptorpharma.com | Novato, United States | 2005 | Sep 2016 | $800M | |
Biologic medicines are developed and manufactured for serious illnesses. | crealtapharma.com | Lake Forest, United States | 2013 | Dec 2015 | $510M | |
Developer of protein based therapeutics for the treatment of chronic granulomatous disease and malignant osteopetrosis | vidararx.com | Alpharetta, United States | 2011 | Mar 2014 | $660M | |
Circadian cytokine modulator for the treatment of rheumatoid arthritis | nitecpharma.com | Reinach, Switzerland | 2004 | Apr 2010 | •••• |
Complete acquisition details for Horizon Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Horizon Therapeutics
9 dated milestones of Horizon Therapeutics across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Horizon Therapeutics is founded.
- Funding First funding round of $17.0M.
- Acquisition Acquires Nitec Pharma.
- Acquisition Acquires Vidara Therapeutics.
- Funding Latest funding round, Post-IPO, of $69.4M.
- Acquisition Acquires Crealta Pharmaceuticals.
- Acquisition Acquires Raptor Pharma.
- Acquisition Acquires Viela Bio.
- Exit Acquired by Amgen.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Horizon Therapeutics
Complete news archive for Horizon Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Horizon Therapeutics
Horizon Therapeutics was founded in 2008.
Horizon Therapeutics is headquartered in Dublin, Ireland.
Timothy Walbert is the CEO of Horizon Therapeutics, as recorded in our data.
Horizon Therapeutics is a funded company, having raised a total of $61.78M across 7 funding rounds to date. The company's 1st funding round was a Series B of $17M, raised on Oct 2008.
Annual revenue of Horizon Therapeutics is $617.41M as on Dec 31, 2022.
Developer of drugs for treating rare and autoimmune diseases. The lead candidates of the company are UPLIZNA fucosylated IgG 1 kappa (IgG1κ) monoclonal antibodies for myasthenia gravis, HZN-825 for idiopathic pulmonary fibrosis, and HZN-4920 for focal segmental glomerulosclerosis as well as kidney transplant rejection, rheumatoid arthritis, and Sjogrens syndrome.
Horizon Therapeutics offers Biologic Medicines, DNA Encoded Libraries, and ATOMIC Model.
Horizon Therapeutics has made 5 acquisitions, including Crealta Pharmaceuticals, Nitec Pharma, and Raptor Pharma.
Horizon Therapeutics has 1 investor. Key investors include Amgen.
Horizon Therapeutics operates through Amgen Inc..
Yes. Horizon Therapeutics was acquired by Amgen in December 2022.